Innovation in Personalized Cannabis Care
February 16th, 2018
Exclusive, Feature Stories, News
Imagine walking into a dispensary for the first time to help alleviate a medical condition. You might come across dozens of different cannabis varieties. These products may be available in buds, oils, capsules, edibles, patches and other forms. And once you decide on the right product, you might receive different advice from different people about how much you should consume.
There are 779 different strains of cannabis being actively cultivated and differences between cannabinoid and terpene profiles, delivery mechanisms, and even an individual’s own metabolism can yield very different experiences between medical marijuana patients. This makes strain selection, delivery mechanisms, and dosing incredibly important for effective treatment of underlying medical conditions.
Resolve Digital Health Inc. aims to improve the patient experience by introducing a Smart Inhaler that allows patients to access the best strain for their condition and fine-tune the exact dose to their personal needs at any given point in time – a methodology they refer to as personalized medicine.
Personalized Medicine’s Potential
Western physicians have traditionally relied on a “one size fits all” approach when it comes to prescribing pharmaceuticals and treatments for their patients. This is rapidly changing with the introduction of personalized medicine, which tailors medical decisions, prescriptions, practices, and interventions to an individual rather than generalizing it to a population. The result is a vastly superior patient experience and clinical outcomes in most cases.
The global personalized medicine industry is projected to grow at a 9.4% compound annual growth rate to approximately $233.4 billion by 2025, according to Research and Markets. Some of the most prominent trends in the market include the rising use of biomarkers for personalized medicine cancer therapy, genomic medicine that incorporates a patient’s genetic profile, and medical devices that offer better diagnostic potential.
As the legal cannabis market matures, Resolve believes that personalized medicine will help improve outcomes given the significant variability between patients. The company’s Smart Inhaler brings the personalized medical advantages home to all manner of medical marijuana patients by suggesting appropriate dosing for an individual and even adjusting the suggestion based on the status of the patient’s condition at that particular time.
Resolve’s Unique Solution
Resolve Digital Health has designed a patient driven model whereby patients assert more control over their treatment in collaboration with their doctor and other healthcare professionals. Powered by artificial intelligence, the device learns about the patient, their condition and how they react to the cannabis treatments. It uses that information to personalize the treatment schedule and dosing suggestions.
The Smart Inhaler enables medical cannabis patients to customize their dosing based on medical conditions, prescriptions, family history, lifestyle, and tolerance. Patients log their experience directly into the device to share with doctors, pharmacists, and caregivers, essentially closing the feedback loop between patients and caregivers. This data can be used to monitor efficacy and continuously improve the cannabis experience over time.
“We strongly believe in the personalized medicine model” says Resolve’s CEO, Rob Adelson. “By empowering patients to become active participants in their own health care, we believe they’ll regain a sense of control and freedom. Furthermore, by applying medical standards to cannabis care and combining them with a high level of personalization we believe our product offers a compelling and safer alternative to many of the opioid based pharmaceuticals that are currently being prescribed.”
Resolve Digital Health is undertaking clinical trials to evaluate the use of medical cannabis as an alternative or adjunct to opioids for pain management. The company also plans to initiate similar trials of medical cannabis for the treatment of a variety of other conditions, including anxiety, depression, and arthritis. Resolve’s Smart Inhaler is expected to be in market in the second quarter of the year.
For more information, visit the company’s website at www.resolvedigitalhealth.com.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: http://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.